You searched for "EAUN"
Menopause in Aesthetics 2025
Menopause in Aesthetics (MiA) returns for its highly anticipated third year! After two groundbreaking events, MiA 2025 promises to push the boundaries of aesthetic medicine and menopause care. This ever-evolving conference and exhibition puts you at the forefront of one...
Is transperineal prostate biopsy without antibiotic prophylaxis the new gold standard?
Prostate cancer is the second most diagnosed malignancy among men worldwide. Despite substantial advances in MRI–guided diagnostic pathways, prostate biopsy with histopathological evaluation remains indispensable for definitive diagnosis. Historically, transrectal biopsy (TRBx) has been the standard approach; however, concerns regarding...
BPS – a diagnostic enigma
This article from a London teaching hospital presents the results of a Medline search about challenges in bladder pain syndrome. All the known definitions from the American Urological Association (AUA), European Association of Urology (EAU), etc. are given while the...BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...Getting it Right First Time in urology: the implementation phase
The Getting it Right First Time (GIRFT) programme is the largest and most comprehensive initiative to improve the quality and efficiency of individual clinical services that the NHS has ever instigated. The programme falls under the auspices of NHS Improvement...
Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer
Biomarkers play an essential role in the diagnosis and treatment of urothelial cancer (UC), with PD-L1, FGFR, and MMR proteins being the most clinically established. These biomarkers, derived from histological specimens, guide therapeutic decisions for bladder cancer (BCa) and upper...
Preoperative stenting compared to non‑stenting in ureteroscopy for urinary stone disease
Urolithiasis, one of the most prevalent urological conditions worldwide, significantly affects patients’ quality of life. In the United States, its lifetime prevalence is approximately 1 in 11, while global rates vary from 1% to 13%. The management of urolithiasis offers...In conversation with Rebecca Porta
We were delighted to chat to Rebecca Porta, the new Chief Executive of The Urology Foundation (TUF) First of all, many congratulations on your recent appointment as Chief Executive of TUF; can you tell us a little bit about your...Still Getting It Right First Time (GIRFT) in urology: meeting the challenges presented by COVID-19
Back in 2019, Simon Harrison – the then sole national lead for the urology workstream in the Getting It Right First Time (GIRFT) programme – wrote an article for Urology News on the GIRFT national report and how its recommendations...
All biochemical recurrences are equal, but some are more equal than others
Despite significant technological advancements, radical prostatectomy (RP) and radiotherapy (RT) are not always effective in curing localised prostate cancer (PCa). Many patients experience a rise in prostate-specific antigen (PSA), known as biochemical recurrence (BCR), leading to considerable anxiety and a...
Management dilemma for very high-risk non–muscle-invasive bladder cancer
The European Association of Urology (EAU) guidelines recommend upfront radical cystectomy (RC) for very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC). However, real-world adoption is limited, as most patients are reluctant to undergo immediate bladder removal. The EAU 2021 risk model...
